Genome editing market: Patterns, vital participants, and provincial

Genome editing is a technique for altering an organism's or cell's DNA. Cutting DNA sequences is used to add or remove DNA from the genome. Genome editing technology allows scientists to alter DNA, changing physical characteristics like eye color and disease risk. 

 

In 2021, the market for genome editing was worth USD 5.06 billion, and by 2030 it will reach USD 21.36 billion, expanding at a 17.33% CAGR during the forecast period. 

 

The genome editing market expansion is driven by the increasing adoption of CRISPR genome editing technology along with the rising demand for synthetic genes in different biotechnology fields.

 

Market Dynamics

 

Trends

 

The fast-evolving CRISPR technology, with its multitude of gene editing applications, propels the evolution of technology. This approach is primarily used to increase access to genetically modified crops by administering gene-editing agents to the plants. Also, this technique is available for use with genetically altered animals in the healthcare and agricultural sectors. The primary purpose of gene editing or genome editing is to alter an organism's DNA. With this technique, genetic material can be introduced, deleted, or replaced at specific spots in the genome.

 

Gene editing is also used to prevent and treat illnesses like cancer, HIV infection, cystic fibrosis, sickle cell disease, and others. Over the forecast period, increased funding for genetic research in developed nations, particularly in North America, will propel the market for gene editing.

 

Restraints

 

Long government approval processes for approving GM items and widespread misconceptions about GM products are the main barriers to the market for genome editing.

 

Opportunity 

 

Genome editing is a technique broadly applicable to plants and has been used to develop agricultural crops for commercial purposes. According to a report by the International Service for the Acquisition of Agro-biotech Applications, Bt cotton accounts for 80% of the total 12 million hectares of cotton grown in India. According to FDA findings, approximately 95% of five crops grown in the United States - corn, soybean, cotton, sugar beets, and canola - used crop seeds developed through plant genome editing. Further study in plant genetic engineering will lead to additional applications that will help botanists and agriculturalists since crops are already cultivated commercially using GM seeds. Hence, the market for genome editing will expand rapidly in the agriculture sector in the coming years. 

Market Segmentation 

 

By Technology

 

On the basis of technology, the market is segment into ZFN, TALEN, CRISPR, antisense, and other technology.

 

In 2022, the CRISPR technology segment held a maximum position in the market. It is mainly due to its rapid use in biotechnology, agriculture, and healthcare. CRISPR research is being conduct to detect treatment for severe conditions like Huntington's disease and human immunodeficiency. Furthermore, the CRISPR techniques are broadly utilize in numerous research and test, which will boost the growth of this market segment. 

 

By Application

 

On the basis of application, the genome editing market is segment into animal genetic engineering, plant genetic engineering, gene therapy, and microorganism genetic engineering. 

 

In the year 2022, the gene therapy segment led the market with a significant revenue share. For cell lines, the DNA and Cell technology are couple together. The advancement of rational genetic engineering to increase biotherapeutic proteins has been hasten by publishing the genomic sequences of many Chinese Hamster Ovary (CHO) cell lines. Due to CRISPR technology, scientists working with CHO have understood the molecular mechanisms driving high-level protein production and important Product Quality Attributes (PQAs). 

 

By End-User 

 

On the basis of end-User, the market is segment into biotechnology companies, academic research institutes, government research institutes, and pharmaceutical companies. 

 

In 2020, the biotechnology and pharmaceutical company segment led the market with 48.4% of the revenue share. The largest market share is due to the expanding research activities for developing cutting-edge therapies. 

Aside from this, constant mechanical progressions in quality altering devices are a significant contributing variable for income age in this market. For example, in April 2021, specialists from Wyss Foundation for Naturally Roused Designing at Harvard created Retron Library Recombineering (RLR) - another quality altering device that empowered the exhibition of millions of hereditary trials at the same time, in this way giving better altering rates. There has been an expanded spotlight on the profoundly versatile CRISPR innovation.

 

Regional Analysis 

 

North America was the largest regional market in 2022, with a revenue share of nearly 30%. This results from the surge of rare diseases in the United States and Canada. Between 25 and 30 million Americans are affect by about 7,000 uncommon diseases, according to the National Institutes of Health (NIH). As a result, with the adoption of new gene-editing tools and technologies, there is a greater need to develop medications to treat rare disorders. Also, the expansion of the gene-editing market will be drive by the presence of major industry players in North America.

 

 

Asia Pacific will emerge as the second-largest regional market. This is due to the growing number of research organizations in developing nations. Large corporations are leaning toward creating gene editing techniques that will support the expansion of the local industry. Moreover, rising R&D efforts in China, India, and Japan will advance regional market trends.

 

Key Players

 

• Vigene Biosciences
• Trans-postage Bio-pharmaceuticals
• Tecan Life-Sciences
• Thermo Fisher Scientific
• PerkinElmer
• Synthego
• Sangamo Therapeutics
• Recombinetics
• Regeneron Pharmaceuticals
• Precision Biosciences
• OriGene Technologies
• New England Biolabs
• GenScript
• Merck
• Lonza
• Integrated DNA Technologies
• Intellia Therapeutics
• Horizon Discovery Group Plc.
• CRISPR Therapeutics
• Creative Biogene
• Cellectis S.A.
• Editas Medicine
• Beren Therapeutics
• Caribou Biosciences
• Agilent Technologies
• Bluebird Bio
• Beam Therapeutics

 

 

In 2021, the market for genome editing was worth USD 5.06 billion, and by 2030 it will reach USD 21.36 billion, expanding at a 17.33% CAGR during the forecast period. The market for genome editing is driven by the rising rate of cancer & other genetic disorder, the rising desire for personalized medicine, and technological developments.

 

Related Reports:

Recombinant DNA Technology Market Report - The global recombinant DNA technology market will witness a robust CAGR of 7.7%, valued at $707.20 billion in 2021, expected to appreciate and reach $1378.76 billion by 2030, confirms Strategic Market Research. Recombinant DNA Technology (rDNA technology) uses enzymes and technology to split or combine a single or multiple genes as required and introduce them into a new organism to achieve a new, desired characteristic.